These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10875684)

  • 1. Pharmacokinetics of the anticoagulant 14C-DX-9065a in the healthy male volunteer after a single intravenous dose.
    Murayama N; McMahon H; Young CG; McCracken NW; Okamura Y; Hakusui H; Tanaka M
    Xenobiotica; 2000 May; 30(5):515-21. PubMed ID: 10875684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.
    Murayama N; Tanaka M; Kunitada S; Yamada H; Inoue T; Terada Y; Fujita M; Ikeda Y
    Clin Pharmacol Ther; 1999 Sep; 66(3):258-64. PubMed ID: 10511061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
    Alexander JH; Dyke CK; Yang H; Becker RC; Hasselblad V; Zillman LA; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Saint-Jacques H; Chetcuti S; Burton JR; Buergler JM; Spence FP; Shimoto Y; Robertson TL; Kunitada S; Bovill EG; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2004 Feb; 2(2):234-41. PubMed ID: 14995984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-performance liquid chromatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction.
    Murayama N; Sudo K
    J Chromatogr B Biomed Sci Appl; 1997 May; 692(2):389-96. PubMed ID: 9188828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant.
    Fujii Y; Takahashi M; Morita H; Kikuchi H; Aramaki Y; Amidon GL
    Drug Metab Pharmacokinet; 2007 Feb; 22(1):26-32. PubMed ID: 17329908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
    Dyke CK; Becker RC; Kleiman NS; Hochman JS; Bovill EG; Lincoff AM; Gerstenblith G; Dzavik V; Gardner LH; Hasselblad V; Zillman LA; Shimoto Y; Robertson TL; Kunitada S; Armstrong PW; Harrington RA
    Circulation; 2002 May; 105(20):2385-91. PubMed ID: 12021225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma.
    Murayama N; Tanaka S; Kikuchi T; Nakaoka M; Sudo K
    J Pharm Biomed Anal; 1996 Aug; 14(11):1435-45. PubMed ID: 8877849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DX-9065a, a direct inhibitor of factor Xa.
    Kaiser B
    Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats.
    Mano Y; Sonoda T; Nakamura E; Usui T; Kamimura H
    Biopharm Drug Dispos; 2004 Sep; 25(6):253-60. PubMed ID: 15334624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of metabolites of [14C]zonampanel, an a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers.
    Minematsu T; Sohda KY; Hashimoto T; Imai H; Usui T; Kamimura H
    Xenobiotica; 2005 Apr; 35(4):359-71. PubMed ID: 16019957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute intravenous and inhalation pharmacokinetics of 2,4-pentanedione in the Fischer 344 rat.
    Frantz SW; Ballantyne B; Leung HW
    Toxicol Ind Health; 1998; 14(3):413-28. PubMed ID: 9569447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and metabolism of triclopyr 3,5,6-trichloro-2-pyridinyloxyacetic acid) in Fischer 344 rats.
    Timchalk C; Dryzga MD; Kastl PE
    Toxicology; 1990 May; 62(1):71-87. PubMed ID: 2343458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of lysosomes to concentrative uptake of DX-9065a into rat liver.
    Murayama N; Nakaoka M; Sudo K
    J Pharm Sci; 2006 Aug; 95(8):1763-70. PubMed ID: 16795022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
    Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
    Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.
    Becker RC; Alexander JH; Li Y; Robertson T; Kunitada S; Spencer FA; Yang H; Harrington RA
    J Thromb Thrombolysis; 2004 Dec; 18(3):193-7. PubMed ID: 15815881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review.
    Setnikar I; Rovati LC
    Arzneimittelforschung; 2001 Sep; 51(9):699-725. PubMed ID: 11642003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.